
Biosimilars Implementation in the United States: Where Opportunities Remain
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Myeloma, So Many Therapeutic Options in the Relapse Setting: How to Sequence Them?
Jonathan Kaufman, MD

Chimeric Antigen Receptor T-Cell Therapy: Indications and Remaining Challenges
Mohamed Kharfan-Dabaja, MD

New Agents and New Toxicities in Malignant Hematology: BCL2 Inhibitors, Anti-BCMA, and FLT3 Inhibitors
Nicole Ianniello, PharmD